Karen Gelmon

6.9k total citations · 4 hit papers
29 papers, 4.2k citations indexed

About

Karen Gelmon is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Karen Gelmon has authored 29 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 12 papers in Cancer Research and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Karen Gelmon's work include Breast Cancer Treatment Studies (11 papers), HER2/EGFR in Cancer Research (10 papers) and Cancer Treatment and Pharmacology (6 papers). Karen Gelmon is often cited by papers focused on Breast Cancer Treatment Studies (11 papers), HER2/EGFR in Cancer Research (10 papers) and Cancer Treatment and Pharmacology (6 papers). Karen Gelmon collaborates with scholars based in Canada, United States and Japan. Karen Gelmon's co-authors include Maggie C.U. Cheang, Torsten O. Nielsen, Scott Tyldesley, Hagen F. Kennecke, K. David Voduc, Sharon H. Giordano, Clifford A. Hudis, Eric P. Winer, Jennifer J. Griggs and Holly Anderson and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Karen Gelmon

29 papers receiving 4.0k citations

Hit Papers

Breast Cancer Subtypes an... 2005 2026 2012 2019 2010 2005 2010 2014 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Breast Cancer Subtypes and the Risk of Local and Regional Relapse
    2010 960 citations Maggie C.U. Cheang, Karen Gelmon et al. Journal of Clinical Oncology profile →
  2. Locoregional Radiation Therapy in Patients With High-Risk Breast Cancer Receiving Adjuvant Chemotherapy: 20-Year Results of the British Columbia Randomized Trial
    2005 757 citations Joseph Ragaz, Ivo A. Olivotto et al. JNCI Journal of the National Cancer Institute profile →
  3. American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
    2010 612 citations Harold J. Burstein, Holly Anderson et al. Journal of Clinical Oncology profile →
  4. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
    2014 559 citations Harold J. Burstein, Holly Anderson et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karen Gelmon Canada 18 2.1k 1.9k 1.0k 813 705 29 4.2k
Ismail Jatoi United States 33 2.4k 1.1× 1.9k 1.0× 1.1k 1.1× 745 0.9× 449 0.6× 141 4.5k
Larissa A. Korde United States 27 1.7k 0.8× 1.0k 0.5× 810 0.8× 681 0.8× 767 1.1× 81 3.7k
M. Castiglione Switzerland 26 2.8k 1.3× 2.5k 1.3× 879 0.9× 786 1.0× 835 1.2× 48 5.0k
Christos Markopoulos Greece 33 2.5k 1.2× 1.7k 0.9× 1.0k 1.0× 569 0.7× 615 0.9× 198 4.7k
Diana Crivellari Italy 37 3.3k 1.6× 2.1k 1.1× 681 0.7× 736 0.9× 1.2k 1.7× 152 4.9k
Byeong‐Woo Park South Korea 42 2.4k 1.1× 2.4k 1.2× 629 0.6× 1.5k 1.8× 766 1.1× 210 5.3k
R.W. Blamey United Kingdom 38 2.7k 1.3× 2.3k 1.2× 1.7k 1.6× 1.2k 1.4× 735 1.0× 130 5.2k
Abenaa M. Brewster United States 32 2.2k 1.1× 1.5k 0.8× 706 0.7× 536 0.7× 408 0.6× 114 3.8k
Peter Barrett‐Lee United Kingdom 35 2.6k 1.2× 1.4k 0.7× 586 0.6× 470 0.6× 671 1.0× 121 5.0k
Olivia Pagani Switzerland 42 3.4k 1.6× 1.8k 0.9× 1.3k 1.3× 435 0.5× 1.5k 2.2× 159 5.5k

Countries citing papers authored by Karen Gelmon

Since Specialization
Citations

This map shows the geographic impact of Karen Gelmon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Gelmon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Gelmon more than expected).

Fields of papers citing papers by Karen Gelmon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Gelmon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Gelmon. The network helps show where Karen Gelmon may publish in the future.

Co-authorship network of co-authors of Karen Gelmon

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Gelmon. A scholar is included among the top collaborators of Karen Gelmon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Gelmon. Karen Gelmon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Irene, Colleen McGahan, Diego Villa, et al.. (2022). The clinical impact of COVID-19 on patients with cancer in British Columbia: An observational study. Heliyon. 8(12). e12140–e12140. 3 indexed citations
2.
Burstein, Harold J., Christina Lacchetti, Holly Anderson, et al.. (2016). Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. Journal of Clinical Oncology. 34(14). 1689–1701. 210 indexed citations
3.
Nguyen, Minh, Shuichi Miyakawa, Junichi Kato, et al.. (2015). Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma. Clinical Cancer Research. 21(24). 5552–5562. 19 indexed citations
4.
Pataky, Reka, Zahra Ismail, Andrew J. Coldman, et al.. (2014). Cost-effectiveness of annual versus biennial screening mammography for women with high mammographic breast density. Journal of Medical Screening. 21(4). 180–188. 16 indexed citations
5.
Korde, Larissa A., Jo Anne Zujewski, Sharon H. Giordano, et al.. (2010). Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations. Journal of Clinical Oncology. 28(12). 2114–2122. 303 indexed citations
6.
Ellard, Susan, Mace L. Rothenberg, Roger Cohen, et al.. (2009). Abstract #3603: ARRY-334543 in ErbB2 positive metastatic breast cancer and other ErbB expressing-cancers: experience from expansion cohorts on a phase I study. Cancer Research. 69. 3603–3603. 2 indexed citations
7.
Courneya, Kerry S., Donald C. McKenzie, Robert D. Reid, et al.. (2008). Barriers to Supervised Exercise Training in a Randomized Controlled Trial of Breast Cancer Patients Receiving Chemotherapy. Annals of Behavioral Medicine. 35(1). 116–122. 112 indexed citations
8.
Gelmon, Karen. (2007). Prescribing extended adjuvant letrozole. The Breast. 16(5). 446–455. 2 indexed citations
9.
Wiseman, Sam M., Nikita Makretsov, Torsten O. Nielsen, et al.. (2005). Coexpression of the type 1 growth factor receptor family members HER‐1, HER‐2, and HER‐3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer. 103(9). 1770–1777. 88 indexed citations
10.
Ragaz, Joseph, Ivo A. Olivotto, John J. Spinelli, et al.. (2005). Locoregional Radiation Therapy in Patients With High-Risk Breast Cancer Receiving Adjuvant Chemotherapy: 20-Year Results of the British Columbia Randomized Trial. JNCI Journal of the National Cancer Institute. 97(2). 116–126. 757 indexed citations breakdown →
11.
Olivotto, Ivo A., Chris Bajdik, Peter M. Ravdin, et al.. (2004). An independent population-based validation of the adjuvant decision-aid for stage I-II breast cancer. Journal of Clinical Oncology. 22(14_suppl). 522–522. 3 indexed citations
12.
Leyland‐Jones, Brian, Andrew Arnold, Karen Gelmon, et al.. (2001). Pharmacologic insights into the future of trastuzumab. Annals of Oncology. 12. S43–S47. 16 indexed citations
13.
Gelmon, Karen, Elizabeth A. Eisenhauer, C. Bryce, et al.. (1999). Randomized Phase II Study of High-Dose Paclitaxel With or Without Amifostine in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology. 17(10). 3038–3047. 75 indexed citations
14.
15.
Munk, Peter L., P Y Poon, John X. OʼConnell, et al.. (1997). Osteoblastic metastases from breast carcinoma with false-negative bone scan. Skeletal Radiology. 26(7). 434–437. 7 indexed citations
16.
Goss, Paul E., Karen Gelmon, Leona Rudinskas, et al.. (1997). Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer. Cancer Chemotherapy and Pharmacology. 41(1). 53–60. 3 indexed citations
17.
Kirkbride, Peter, Karen Gelmon, Elizabeth A. Eisenhauer, B. Fisher, & Hélène Dulude. (1997). A phase I/II study of paclitaxel (Taxol®) and concurrent radiotherapy in advanced nonsmall cell lung cancer. International Journal of Radiation Oncology*Biology*Physics. 39(5). 1107–1111. 17 indexed citations
18.
Arnold, Andrew, et al.. (1994). Phase II Trial of 13-cis-Retinoic Acid Plus Interferon   in Non-Small-Cell Lung Cancer: For the National Cancer Instit ute of Canada Clinical Trials Group. JNCI Journal of the National Cancer Institute. 86(4). 306–309. 17 indexed citations
19.
Osoba, David, et al.. (1994). Quality of life, appetite, and weight change in patients receiving dose-intensive chemotherapy.. PubMed. 8(4). 61–5; discussion 65. 35 indexed citations
20.
Gelmon, Karen. (1990). AIDS, San Francisco. The Lancet. 335(8705). 1581–1582. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ismail Jatoi Breakdown of academic impact, for papers by Larissa A. Korde Breakdown of academic impact, for papers by M. Castiglione Breakdown of academic impact, for papers by Christos Markopoulos Breakdown of academic impact, for papers by Diana Crivellari Breakdown of academic impact, for papers by Byeong‐Woo Park Breakdown of academic impact, for papers by R.W. Blamey Breakdown of academic impact, for papers by Abenaa M. Brewster Breakdown of academic impact, for papers by Peter Barrett‐Lee Breakdown of academic impact, for papers by Olivia Pagani
Rankless by CCL
2026